Generics 5

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Cloperastine fendizoate manufacturers

5 products found

Filters

5 products found

cloperastine fendizoate

Oral solution 708 mg/100 ml - 100ml, 200ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #17473
A pharmaceutical manufacturer based in the EU that is active in 40+ countries worldwide selling its products in Europe, the Middle East, LATAM, and Asia for 50+ years. The company has partnerships in the EU for production that comply with GMP standards. Key production lines include pharmaceutical products, nutraceuticals, medical devices, and cosmetics. Therapy areas include anti-infectives, anti-inflammatory and dermatological. The company has its R&D and regulatory affairs department for CTD dossier and marketing authorization management.

Manufacturer usually replies in 5 days

cloperastine fendizoate

Syrup 3.54 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Kuwait
Manufacturer #570
A pharmaceutical manufacturer based in the EU that has been active in 80+ countries selling its products for 110+ years. Main therapeutic areas include CNS, respiratory, and women’s health. Main dosage forms include sterile drugs, solid oral, and liquid forms. The company owns 20+ branches in Europe, North America, and Asia. The company possesses manufacturing facilities in Europe, Asia, and LATAM.

Manufacturer usually replies in 8 days

cloperastine fendizoate

Oral solution 3.54 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Portugal , Spain
Comments
Ref: Flutox® (Zambon)
Manufacturer #10578
This pharmaceutical company, operating for several decades, is a prominent player in the European market. Their core focus is on generic and biosimilar medications, catering to a broad spectrum of healthcare needs. Their product portfolio includes prescription drugs, over-the-counter medications, and health and nutrition supplements. Their offerings are available in various dosage forms, including solids, injectables, and liquids. The company holds a strong track record in the industry, with GMP certifications for their production lines in the EU and North America. They also engage in manufacturing for other pharmaceutical companies. Key therapy areas covered by their products include cardiology, oncology, and women's health. Their dedication to quality and extensive product range position them as a leading force in the pharmaceutical landscape.

Manufacturer usually replies in 8 days

Want to see all 5 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Cloperastine Fendizoate manufacturers

What is Cloperastine Fendizoate?

Cloperastine Fendizoate is a medication used to treat coughs and cold symptoms, such as runny nose, sneezing, and cough. It is an anti-tussive, which helps to suppress coughing, and an antihistamine, which helps to relieve symptoms of allergies, the common cold, acute bronchitis, chronic bronchitis, bronchiectasis and lung tuberculosis.

Cloperastine Fendizoate works by blocking the effects of histamine, a chemical responsible for many of the symptoms of allergies and the common cold, and by suppressing the cough reflex.

Cloperastine Fendizoate is sometimes referred to by other names, including Cloperastine, Cloperastin, and Cloperastine hydrochloride. These names all refer to the same medication.

Cloperastine Fendizoate brand name and patent information

Cloperastine Fendizoate is approved for sale in Japan, Hong Kong, and parts of the European Union. The medication is sold under the brand names Hustazol, Nitossil, and Seki among others. Friedrich Bossert, Wolf Vater, and Kurt Bauer filed for the first patents back in 1971. It was first approved for sale in Japan in 1972, followed by its first launch in Italy in 1981. It is not approved for sale in the USA.

Cloperastine Fendizoate forms and dosage

Cloperastine Fendizoate is available in the form of syrup and tablets. The exact dose and frequency of administration depend on several factors, including the patient's age, weight, overall health, and the severity of the symptoms being treated.

The recommended dose for adults is 1 to 2 tablets (5-10 mg) or 5-10 mL of syrup taken three to four times daily. For children, the dose may be lower and is based on the child's weight. The recommended dose and administration of Cloperastine Fendizoate may vary based on the form and specific indication.

It is also important to note that Cloperastine Fendizoate may cause drowsiness, so avoiding activities requiring alertness, such as driving or operating heavy machinery, is essential.

The price of Cloperastine Fendizoate

The price of one injection of 1 ml in a 10 mn DMSO solution costs 25 USD in the international market. The API ingredient version of this medicine costs around 50 USD for a supply of 98% pure powder of Cloperastine HCL.

How does Cloperastine Fendizoate work?

Cloperastine Fendizoate is a combination medication that contains two active ingredients: Cloperastine and Fendizoate. Cloperastine is an antihistamine that works by blocking the action of histamine, a substance produced by the body during an allergic reaction. This helps to relieve symptoms such as sneezing, runny nose, and itching.

Fendizoate is an antitussive that works by suppressing the cough reflex. This helps to relieve cough symptoms associated with upper respiratory tract infections and allergies.

When these two active ingredients are combined, they work together to provide relief from a range of symptoms associated with upper respiratory tract infections and allergies, including cough and runny nose. However, it is important to note that Cloperastine Fendizoate is not a cure for the underlying conditions but rather a treatment for their symptoms.

Cloperastine Fendizoate’s precise mechanism of action has not been fully understood or established. However, several other studies on its biological activities show that it involved the ligand of the σ1 receptor (Ki = 20 nM), which is likely an agonist of GIRK channel blocker and a potent antihistamine (Ki = 3.8 nM for the H1 receptor, and anticholinergic properties.

Finding Cloperastine Fendizoate Manufacturers and Suppliers

Finding trusted Cloperastine Fendizoate manufacturers and Cloperastine Fendizoate suppliers could be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks.

In addition, it is easy to use an online platform to grow your business opportunities. The convenient search engine makes it easy to search for manufacturers and suppliers of Cloperastine Fendizoate.

The selection of Cloperastine Fendizoate options can be narrowed down with filters and quickly evaluated against one another according to drug prices and commercial terms. The advanced filters help you search for available Cloperastine Fendizoate manufacturers by product ATC class, form, dossier type and readiness, country of origin, GMP approvals and more.

Also, each product card contains essential information about this substance, including clinical data, CPP, stability zones, shelf life, packs, batch sizes, MOQ, available deal types, countries where Cloperastine Fendizoate is already registered or where the specific manufacturer cannot supply the product.

All this information is available to Pipelinepharma registered users and can be seen by logging into the platform free of charge.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation